Causes for concern: is nice failing to uphold its responsibilities to all NHS patients?

Karl Claxton; Mark Sculpher; Stephen Palmer; Anthony J Culyer

doi:10.1002/hec.3130

Causes for concern: is nice failing to uphold its responsibilities to all NHS patients?

Karl Claxton, Mark Sculpher, Stephen Palmer, Anthony J Culyer

Research output: Contribution to journal › Article

Abstract

Organisations across diverse health care systems making decisions about the funding of new medical technologies face extensive stakeholder and political pressures. As a consequence, there is quite understandable pressure to take account of other attributes of benefit and to fund technologies, even when the opportunity costs are likely exceed the benefits they offer. Recent evidence suggests that NICE technology appraisal is already approving drugs where more health is likely to be lost than gained. Also, NICE recently proposed increasing the upper bound of the cost-effectiveness threshold to reflect other attributes of benefit but without a proper assessment of the type of benefits that are expected to be displaced. It appears that NICE has taken a direction of travel, which means that more harm than good is being, and will continue to be, done, but it is unidentified NHS patients who bear the real opportunity costs. Copyright © 2014 John Wiley & Sons, Ltd.

Original language	English
Pages (from-to)	1-7
Number of pages	7
Journal	Health Economics
Volume	24
Issue number	1
DOIs	https://doi.org/10.1002/hec.3130
Publication status	Published - 7 Jan 2015

Bibliographical note

Access to Document

10.1002/hec.3130

Cite this

@article{2f04f14ef1b14f59be1f23a9579e5393,

title = "Causes for concern: is nice failing to uphold its responsibilities to all NHS patients?",

abstract = "Organisations across diverse health care systems making decisions about the funding of new medical technologies face extensive stakeholder and political pressures. As a consequence, there is quite understandable pressure to take account of other attributes of benefit and to fund technologies, even when the opportunity costs are likely exceed the benefits they offer. Recent evidence suggests that NICE technology appraisal is already approving drugs where more health is likely to be lost than gained. Also, NICE recently proposed increasing the upper bound of the cost-effectiveness threshold to reflect other attributes of benefit but without a proper assessment of the type of benefits that are expected to be displaced. It appears that NICE has taken a direction of travel, which means that more harm than good is being, and will continue to be, done, but it is unidentified NHS patients who bear the real opportunity costs. Copyright {\textcopyright} 2014 John Wiley & Sons, Ltd.",

author = "Karl Claxton and Mark Sculpher and Stephen Palmer and Culyer, {Anthony J}",

note = "Copyright {\textcopyright} 2014 John Wiley & Sons, Ltd.",

year = "2015",

month = jan,

day = "7",

doi = "10.1002/hec.3130",

language = "English",

volume = "24",

pages = "1--7",

journal = "Health Economics",

issn = "1057-9230",

publisher = "Wiley-Blackwell",

number = "1",

}

TY - JOUR

T1 - Causes for concern

T2 - is nice failing to uphold its responsibilities to all NHS patients?

AU - Claxton, Karl

AU - Sculpher, Mark

AU - Palmer, Stephen

AU - Culyer, Anthony J

PY - 2015/1/7

Y1 - 2015/1/7

N2 - Organisations across diverse health care systems making decisions about the funding of new medical technologies face extensive stakeholder and political pressures. As a consequence, there is quite understandable pressure to take account of other attributes of benefit and to fund technologies, even when the opportunity costs are likely exceed the benefits they offer. Recent evidence suggests that NICE technology appraisal is already approving drugs where more health is likely to be lost than gained. Also, NICE recently proposed increasing the upper bound of the cost-effectiveness threshold to reflect other attributes of benefit but without a proper assessment of the type of benefits that are expected to be displaced. It appears that NICE has taken a direction of travel, which means that more harm than good is being, and will continue to be, done, but it is unidentified NHS patients who bear the real opportunity costs. Copyright © 2014 John Wiley & Sons, Ltd.

AB - Organisations across diverse health care systems making decisions about the funding of new medical technologies face extensive stakeholder and political pressures. As a consequence, there is quite understandable pressure to take account of other attributes of benefit and to fund technologies, even when the opportunity costs are likely exceed the benefits they offer. Recent evidence suggests that NICE technology appraisal is already approving drugs where more health is likely to be lost than gained. Also, NICE recently proposed increasing the upper bound of the cost-effectiveness threshold to reflect other attributes of benefit but without a proper assessment of the type of benefits that are expected to be displaced. It appears that NICE has taken a direction of travel, which means that more harm than good is being, and will continue to be, done, but it is unidentified NHS patients who bear the real opportunity costs. Copyright © 2014 John Wiley & Sons, Ltd.

U2 - 10.1002/hec.3130

DO - 10.1002/hec.3130

M3 - Article

C2 - 25488707

SN - 1057-9230

VL - 24

SP - 1

EP - 7

JO - Health Economics

JF - Health Economics

IS - 1

ER -